Tillmann Taube

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

Vivek Patel, Matthieu Mahévas, Soo Yong Lee et al. · Blood · 2012 · 344 citations · Full text

Medicine, Hematology, Immunology +7

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Hartmut Döhner, Michael Lübbert, Walter Fiedler et al. · Blood · 2014 · 229 citations · Full text

Medicine, Pharmacology, Chemotherapy +9

Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology

Sven Wellmann, Tillmann Taube, Krisztina Paál et al. · Clinical Chemistry · 2001 · 94 citations

Medicine, Molecular Biology, Oncology +16

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

C-C. Lin, Wu‐Chou Su, C-J. Yen et al. · British Journal of Cancer · 2014 · 78 citations · Full text

Medicine, Oncology, Pharmacology +16

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

Nathalie Gaspar, Lynley V. Marshall, Debbie Binner et al. · Annals of Oncology · 2018 · 77 citations · Full text

Pharmacy, Oncology, Pediatrics +14